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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and
Allergies (NDA) was asked to deliver an opinion on D-ribose as a novel food (NF) pursuant to Regulation
(EU) 2015/2283. The applicant intends to market the NF as ingredient in a variety of foods, food
supplements and in certain foods for speciﬁc groups. The NF is produced by fermentation using a
transketolase-deﬁcient strain of Bacillus subtilis and marketed as Bioenergy RiboseTM. The information
provided on the batch-to-batch variability, speciﬁcations, stability, production process and history of the
organism used as a source of the NF is sufﬁcient and does not raise safety concerns. The Panel considers
that the effects observed in a subchronic toxicity study in rats could be the consequence of nutritional
imbalances, but toxicological effects could not be ruled out; from this study, the Panel derived a No
observed adverse effect level (NOAEL) of 3.6 g/kg body weight (bw) per day. From the human studies
indicating a potential decrease in glucose levels and/or the occurrence of transient symptomatic
hypoglycaemia at intakes of 10 g of D-ribose, the Panel deﬁned 70 mg/kg bw per day as the NOAEL
with respect to hypoglycaemia that can be considered applicable for adults. For children, the
Panel acknowledges the lack of human data directly relevant for this population group. Based on the
NOAEL derived from the subchronic toxicity study in rats, an acceptable level of intake of 36 mg/kg bw
per day was deﬁned that would also take into account the potentially increased sensitivity of certain
population groups to hypoglycaemia. The Panel concludes that the NF is safe for the general population
at intake levels up to 36 mg/kg bw per day and considers that the safety of the NF at the intended uses
and use levels as proposed by the applicant has not been established.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the European food Safety Authority (EFSA)
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientiﬁc opinion on
D-ribose as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The assessment of the safety of
this NF, which follows the methodology set out in the EFSA Guidance for the preparation and
presentation of an application for authorisation of a NF1 according to Regulation (EU) 2015/2283 and
in the Commission Implementing Regulation (EU) 2017/2469, is based on the data supplied in the
application, the initial assessment by the competent authority of the United Kingdom, the concerns
and objections of a scientiﬁc nature raised by the other Member States and the responses of the
applicant, the information submitted by the applicant following EFSA requests for supplementary
information and additional data identiﬁed by the Panel.
The NF which is the subject of the application is D-ribose produced by fermentation using a
transketolase-deﬁcient strain of Bacillus subtilis and marketed as Bioenergy RiboseTM.
The information provided on the batch-to-batch variability, stability, speciﬁcations, production
process, and history of the organism used as a source of the NF is sufﬁcient and does not raise safety
concerns.
The applicant intends to market the NF as an ingredient in a variety of foods, food supplements
and in certain foods for speciﬁc groups (total diet replacement for weight control and food for special
medical purposes). The maximum proposed use levels range from 0.31 to 5 g/100 g in fortiﬁed foods
and up to 10 g/day in food supplements.
Based on the proposed uses and maximum use levels and the individual food consumption data
from the EFSA Comprehensive Food Consumption Database, the Panel estimated the range of the 95th
percentile anticipated intakes of the NF in the European Union (EU) from the consumption of fortiﬁed
foods only (Table 4). These ranges are: 27–829 mg/kg body weight (bw) per day for infants,
136–553 mg/kg bw per day for toddlers, 102–314 mg/kg bw per day for children, 51–154 mg/kg bw
per day for adolescents, 32–106 mg/kg bw per day for adults and 26–93 mg/kg bw per day for the
elderly. The expected intake of the NF from food supplements in the target population would be up to
163 mg/kg bw per day for adolescents and 143 mg/kg bw per day for adults.
The Panel acknowledges the limited information available to estimate the intake levels of D-ribose
from the background diet and the extent of its daily endogenous production, and is therefore not in
the position to estimate the contribution of these sources to the combined intake of the NF.
Considering the possible scenario of combined intake of the NF from fortiﬁed foods and from
food supplements, the estimated intake for the 95th percentile of the target population would be
214–317 mg/kg bw per day for adolescents and 175–249 mg/kg bw per day for adults and
169–236 mg/kg bw per day for the elderly.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
The Panel considers that the microbiological information provided does not raise safety concerns.
The Panel notes that the risk of allergenicity is low.
Based on the genotoxicity tests provided, the Panel concludes that there are no concerns regarding
genotoxicity of the NF.
The information on absorption and excretion of D-ribose in rats is limited. The available data
indicate that in humans, D-ribose is rapidly and nearly completely absorbed when administered at
200 mg/kg bw per hour for 5 h. In humans, at dose levels above 3 g (about 40 mg/kg bw),
absorption was faster than metabolism. Application of D-ribose with meals decreases absorption. In the
body, D-ribose is converted mainly to glucose via the pentose phosphate pathway, rather than nucleic
acid precursors, which then is further used in the metabolism/biosynthesis. Part of the ribose and its
metabolites is excreted via the urine and the percentage increases with increasing dose.
In a subchronic toxicity study, Wistar rats were administered diets containing the NF at levels of
0.0, 3.6, 7.6 and 15.0 g/kg bw per day in the male groups and 0.0, 4.4, 8.5 and 15.7 g/kg bw per day
in the female groups. The most prominent ﬁndings in this study are effects on body weight, increases
in water intake and urine volume (and dilution of the urine), full and empty caecum weight, liver and
1 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283.
EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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other organ weights. Given the high dose levels of D-ribose used in the study, the type of effects
observed in this subchronic study and the high purity of the NF, the Panel considers that the observed
effects could be the consequence of nutritional imbalances, but toxicological effects could not be ruled
out. Therefore, the Panel derived a No observed adverse effect level (NOAEL) of 3.6 g/kg bw per day
based on this study.
In a developmental toxicity study, Wistar rats were mated and the females were administered the
NF from gestational day 0–21 at levels of 0.0, 4.25, 7.94 and 9.91 g/kg bw per day for the different
groups. The Panel notes that besides maternal toxicity (reduced body weight gain), wavy ribs and
delayed ossiﬁcation were detected in the foetuses in the mi D- and high-dose groups. The foetal
skeletal alterations are reported to occur frequently in developmental toxicity studies, often secondary
to maternal toxicity. The NOAEL for maternal/foetotoxicity in this study is consequently 4.25 mg/kg bw
in the diet, while the NOAEL for teratogenicity is 9.91 mg/kg bw per day, the highest dose tested.
Therefore, this study supports the NOAEL from the subchronic study, indicating that metabolic
imbalances affect both the maternal organism and the developing embryo.
Several human studies were provided which were not designed to assess the safety of D-ribose.
The administration of single oral doses of 2–87 g D-ribose consistently report transient decreases of
glucose concentrations within 1–3 h. The transient decrease of glucose concentration was not
associated with clinical symptoms of hypoglycaemia, except for one case, where a low-weight female
experienced short-term symptoms of hypoglycaemia after ingesting 10 g of ribose in the fasted state.
While in this and in most of the other studies, blood glucose levels did not fall below 2.8 mmol/L, a
temporary signiﬁcant decline of blood glucose to 2.6 mmol/L was observed in one study following a
single oral dose of 10 g D-ribose. The decrease in blood glucose comes along with increases in insulin
levels. The glucose-lowering effect occurs also if meals rich in carbohydrate or fat are ingested before
uptake of D-ribose.
No studies have been provided that investigated intake of D-ribose in infants, young children and
adolescents. Whether young age may be of special concern with regard the glucose-lowering effects of
D-ribose is not known. However, the Panel considers that children could be particularly vulnerable to
glucose-lowering effects of D-ribose.
The Panel notes that there is a lack of understanding of the mechanisms responsible for the
short-term decrease in blood glucose reported in the human studies, only limited data on the
dose–response relationship between D-ribose and blood glucose levels, and uncertainty about the risk
of symptomatic hypoglycaemia conditions, especially in susceptible persons.
Because the decrease in glucose levels and/or the occurrence of transient symptomatic
hypoglycaemia (as reported in one case) is considered adverse, based on the human studies, the
lowest observed adverse effect level (LOAEL) would be at intakes of 10 g of D-ribose. Concerning the
human data, taking the above issues into account, the Panel concludes that 5 g per day, equivalent to
70 mg/kg bw per day, would be the NOAEL with respect to hypoglycaemia that can be considered
applicable for adults. For children, the Panel acknowledges the lack of human data directly relevant for
this population group.
For the animal study, the Panel considered an uncertainty factor of 100 as sufﬁcient given the
nature of the NF and the magnitude of the effects observed. Based on the NOAEL of 3,600 mg/kg bw
per day derived from the subchronic toxicity study in rats, an acceptable level of intake would be up to
36 mg/kg bw per day. This is half the NOAEL value identiﬁed in the human studies for adults with
respect to hypoglycaemia. The Panel concludes that 36 mg/kg bw per day would also take into
account the potentially increased sensitivity of certain population groups to hypoglycaemia, including
children.
The Panel therefore concludes that the NF, D-ribose, is safe for the general population at intake
levels up to 36 mg/kg bw per day.
The Panel considers that the safety of the NF at the intended uses and use levels as proposed by
the applicant has not been established.
Safety of D-ribose
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 17 March 2008, the company Bioenergy Lire Science, Inc. submitted a request in accordance
with Article 4 of the Novel Food Regulation (EC) No 258/97 to place on the market D-ribose to the
competent authority of the United Kingdom. However, a request for additional information to resolve
uncertainties arising from a study on reproductive toxicity was made. In November 2013 the company
submitted a revised dossier.
On 23 February 2016, the competent authority of the United Kingdom forwarded to the
Commission its initial assessment report, which came to the conclusion that D-ribose meets the criteria
for acceptance of a NF deﬁned in Article 3(1) of Regulation (EC) No 258/970.
On 17 May 2016, the Commission forwarded the initial assessment report to the other Member
States. Several Member States (MS) submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• No data have been presented by the applicant to show that any signiﬁcant amount of free
D-ribose would be consumed as part of the normal diet. The fact that D-ribose serves as an
endogenous intermediate in metabolic routes in living cells does not imply that it would be
suitable as food.
• The information regarding the metabolic fate of ingested D-ribose relies on old publications
without elaborating if this description is considered to be well-established and sufﬁciently
up-to-date.
• The possibility for combined intake from both fortiﬁed foods and food supplements, although
considered unlikely by the applicant, should be considered as a realistic scenario that could
have a signiﬁcant effect on total intake for high level users.
• The occurrence of gastrointestinal problems, short-term hypoglycaemia and hyperuricemia in
some of the studies presented and the lack of long-term studies analysing the effect of high
doses of D-ribose, does not allow determining the safety and tolerance of a long-term intake of
D-ribose.
• In both a subchronic toxicity study and a developmental toxicity study in rats, effects were
observed in the mid-dose and high-dose groups (wavy ribs and delayed ossiﬁcation). The initial
assessment performed by the UK authority concludes that these effects are not expected to be
relevant for humans at the proposed intake levels. Nevertheless, the observed effects may not
yet be understood sufﬁciently to allow drawing a ﬁrm conclusion.
• A margin of exposure of 21 for toddlers is not considered to be sufﬁcient, as they are a
particularly sensitive group of individuals.
On 19 May 2017 and in accordance with Article 29(1)(a) of Regulation (EU) 178/2002,2 the
Commission asked the European Food Safety Authority to provide a scientiﬁc opinion by carrying out
the additional assessment for D-ribose as a NF in the context of Regulation (EU) No 258/97 and to
consider the elements of a scientiﬁc nature in the comments raised by the other MS.
According to Article 35 (1) of Regulation (EU) 2015/2283,3 any request for placing a novel food on
the market within the Union submitted to a Member State in accordance with Article 4 of Regulation
(EU) 258/1997 and for which the ﬁnal decision has not been taken before 1 January 2018 shall be
treated as an application under this Regulation. This is the case for the present application.
In accordance with Article 10 (3) of Regulation (EU) 2015/2283, EFSA shall give its opinion as to
whether the update of the Union List referred to in Article 10 (1) is liable to have an effect on human
health.
2 Regulation (EU) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
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2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following European Union Food Safety Authority (EFSA)
requests for supplementary information.
During the assessment, the Panel identiﬁed additional data which were not included in the
application.
Administrative and scientiﬁc requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469.4
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application1. As indicated in this guidance, it is
the duty of the applicant to provide all of the available (proprietary, conﬁdential and published)
scientiﬁc data, including both data in favour and not in favour to supporting the safety of the proposed
NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include: Oral
embryotoxicity/teratogenicity study with D-ribose in rats [TNO report V2657], subchronic (13-week)
oral toxicity study with D-ribose in rats [TNO report V99.1155].
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use, and it is not an assessment of the efﬁcacy of D-ribose with regard to any
claimed beneﬁt.
3. Assessment
3.1. Introduction
This application refers to D-ribose as a NF as deﬁned in article 3 of the NF Regulation 2015/2283.
The applicant intends to market the NF as an ingredient in a variety of foods, food supplements and in
certain foods for speciﬁc groups (total diet replacement for weight control and food for special medical
purposes).
3.2. Identity of the NF
The NF which is the subject of the application is D-ribose (marketed as Bioenergy RiboseTM).
Bioenergy RiboseTM is produced by fermentation using a transketolase-deﬁcient strain of
Bacillus subtilis. The production strain is unable to utilise D-ribose, which accumulates in the
fermentation medium.
Chemically, D-ribose (CAS No: 50-69-1; molecular formula: C5H10O5) is an aldopentose
monosaccharide, with a molecular mass of 150.13 Da. In aqueous solution, D-ribose exists in
equilibrium between ﬁve possible chemical structures: one linear form and two-ﬁve-ring (a- and
b-ribofuranose) and two-six-ring forms (a- and b-ribopyranose). Figure 1 represents one of the
structures.
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientiﬁc
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
Safety of D-ribose
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3.3. Production process
Bioenergy RiboseTM is manufactured in accordance with Good manufacturing practice (GMP) in a
Hazard analysis and critical control points (HACCP)-registered and ISO 9001:2000-certiﬁed facility.
Bioenergy employs B. subtilis ATCC No. 21951 (originally designated as Bacillus pumilus), which is a
non-genetically modiﬁed organism. B. subtilis is widely distributed in the environment and is naturally
present in many foods that have been consumed by humans for decades without evidence of adverse
effects (Hui et al., 2004; Logan et al., 2007). In the initial step of the production process, B. subtilis is
cultivated in a nutrient rich medium, followed by fermentation. During fermentation, D-glucose is
converted to D-ribose, which accumulates in the culture broth. In the following production step, the
culture broth is ﬁltered to remove bacteria and bacterial fragments, solid particles and large molecules
and is then puriﬁed and decolourised. Inorganic ions are then removed by ion exchange, and further
ﬁltration removes salts and small molecules. These ﬁltration and puriﬁcation steps are followed by
concentration through evaporation. D-ribose is then crystallised with ethanol out of the concentrated
solution and crystals recovered by centrifugation, dried and packaged.
The absence of residual biomass in the ﬁnal product was conﬁrmed by the results of a Bradford
assay (limit of detection 0.1 lg/mL) on six randomly selected production lots. No protein was detected
in the samples using the method described therefore excluding the presence of residual protein. Upon
request of the UK Advisory Committee on Novel Foods and Processes (ACNFP), the applicant provided
the results of a Kjeldahl assay (limit of detection 0.16%) that did not detect proteins in samples of ﬁve
production lots of D-ribose.
The amounts of residual ethanol from the crystallisation step were analysed in ﬁve production lots.
The analysis reported residual ethanol values ranging from 82 to 170 lg/g.
Finally, the applicant provided a list of control points and general considerations excluding the
presence of potential impurities resulting from the production process.
The Panel considers that the production process is sufﬁciently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided product analysis of ﬁve independent production lots (Table 1). The applicant
indicated that the analyses of Bioenergy RiboseTM are performed according to the methods speciﬁed for
ribose in the United States Pharmacopeia (USP40-NF35, 2017).
O
H H
OH OH
H
OH
HOCH2
H
Figure 1: Chemical structure of D-ribose in its a- D-ribofuranose form
Table 1: Batch-to-batch analyses of the novel food
Parameter
Lot number
M01666501/
20130205
M0276501/
20130206
M0336501/
20130306
M0376501/
20130512
M04066501/
20130515
Appearance (dry with
powdery texture, white to
slightly yellow in colour)
Conforms Conforms Conforms Conforms Conforms
Speciﬁc rotation, [a]D
25 20.1 20.1 20.1 20.2 20.1
Purity, % 99.4 99.3 99.3 98.6 99.2
Loss on drying (moisture),
%
0.15 0.17 0.23 0.36 0.22
Ash, % < 0.1 < 0.1 < 0.1 < 0.1 < 0.1
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The Panel considers that the information provided on the composition of the NF is sufﬁcient and
does not raise safety concerns.
3.4.1. Stability
The applicant provided a summary of stability studies on D-ribose powder tested in its standard
commercial package at room temperature for 24 months (proposed shelf life of Bioenergy RiboseTM). The
test parameters included purity, colour, appearance, moisture content, bulk density and microbial counts.
The product settled and became slightly yellow during storage. The bulk density and purity of the product
decreased slightly. All the microbial counts remained consistent and within the limits of speciﬁcations.
At the request of the Panel, the applicant has provided a study report, including the speciﬁcation of
the methods used to test the parameters, assessing the stability of three additional production lots.
The report provides data on purity, loss on drying, clarity and bulk density at different time points over
24 months. All lots were in line with the previous assessment apart from one lot being slighty below
the expected clarity at the end of the observation period.
The Panel considers that the data provided sufﬁcient information with respect to the stability of
the NF.
3.5. Speciﬁcations
The speciﬁcations proposed for the NF are indicated in Table 2. They include physical and chemical
parameters as well as chemical and biological contaminants.
Parameter
Lot number
M01666501/
20130205
M0276501/
20130206
M0336501/
20130306
M0376501/
20130512
M04066501/
20130515
Clarity of solution, %
transmittance
99.3 99.3 99.5 99.3 99.2
Heavy metals
Lead, mg/kg < 0.005 < 0.005 < 0.005 < 0.005 < 0.005
Arsenic, mg/kg < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Cadmium, mg/kg < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Mercury, mg/kg < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Microbiological speciﬁcations
Total plate count, CFU/g < 10 < 10 < 10 < 10 < 10
Yeast, CFU/g < 10 < 10 < 10 < 10 < 10
Mould, CFU/g < 10 < 10 < 10 < 10 < 10
Coliforms, CFU/g < 10 < 10 < 10 < 10 < 10
Salmonella sp., in 25 g Negative Negative Negative Negative Negative
CFU: colony-forming unit.
Table 2: Speciﬁcations of the NF
Parameter Speciﬁcation Method
Appearance Dry with powdery texture,
white to slightly yellow in colour
Visual inspection
Speciﬁc rotation [a]D
25 19.0 to 21.0° Polarimetry
D-ribose purity 98.0–102.0% dry basis HPLC/RI
Ash < 0.2% Residues on ignition
Loss on drying (moisture) < 0.5% Vacuum oven
Clarity of solution ≥ 95% transmittance Spectrophotometry UV Vis
Heavy metals
Lead ≤ 0.1 mg/kg AOAC 993.14
Arsenic ≤ 0.1 mg/kg AOAC 993.14
Cadmium ≤ 0.1 mg/kg AOAC 993.14
Mercury ≤ 0.1 mg/kg AOAC 993.14
Safety of D-ribose
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2018;16(5):5265
The Panel considers that the information provided on the speciﬁcations of the NF is sufﬁcient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The process for the production of the NF which is the subject of the application employs B. subtilis ATCC
21951. This non-genetically modiﬁed Bacillus strain was obtained through UV mutagenesis and cannot
utilise D-ribose due to a lack of transketolase activity (de Wulf and Vandamme, 1997). D-ribose
accumulating Bacillus strains cannot form spores because two metabolites, ribitol and teichoic acid, derived
from D-ribose, are necessary for spore formation. Due to the inability to form spore, D-ribose-accumulating
cells of this Bacillus strain are more easily killed by heat and dryness than those of wild-type Bacillus.
B. subtilis is included in the list of Qualiﬁed presumption of safety (QPS)-recommended biological
agents intentionally added to food or feed with the qualiﬁcation ‘Absence of toxigenic activity’ (EFSA
BIOHAZ Panel, 2017).
The applicant provided a review of the scientiﬁc literature on the B. subtilis species concluding that this
species is non-toxigenic and non-pathogenic, and that antibiotic resistance would not be expected as there
are no known plasmids in B. subtilis that encode for antibiotic resistance. According to the applicant’s
review, B. subtilis has a long history of safe use in foods and for production of various chemicals including
ribose, riboﬂavin and other metabolites and food ingredients. B. subtilis is involved in the production of
certain fermented food products including soy sauce, tofu, soybean paste and other foods.
The identiﬁcation of the bacterial strain used to produce Bioenergy’s D-ribose was based on cellular
morphology, physical-chemical characteristics and 16S rRNA and gyrB gene sequences. In response to
an EFSA request regarding the identiﬁcation of producer microorganism at strain level, the applicant
provided data of the transketolase and transaldolase gene sequences. These genes that encode two
enzymes of the pentose phosphate pathway (PPP) showed multiple point mutations that allow the
differentiation of the strain from reference strains. It was explained that these mutations lead to loss
of enzymatic activity and, thereby, to D-ribose accumulation.
The production lots presented in Table 1 were also analysed for the presence of the bacterial
lipopolysaccharide (LPS), which is a membrane component of Gram-negative bacteria that could act as
endotoxin, according to the US Pharmacopeia method based on the use of amoebocyte lysate from
the horseshoe crab (USP35-NF30, 2012) and all the samples analysed tested negative. The
Panel notes that for Bacillus species other than the Bacillus cereus group, a cytotoxicity test should be
made to determine whether the strain produces potentially cytotoxic non-ribosomal synthesised
peptides (EFSA FEEDAP Panel, 2014). In response to EFSA’s request, the applicant evaluated the effect
of cell-free culture supernatants of B. subtilis ATCC 21951 on permeability of Vero cell cultures using a
propidium iodide uptake test in line with the EFSA guidance (EFSA FEEDAP Panel, 2014), without
detecting signiﬁcant changes, indicating the absence of toxigenicity.
3.6.2. History of use of the NF
D-ribose is naturally occurring in all living cells and it is synthesised endogenously from the
conversion of glucose via the PPP. Ribose is a component of RNA as well as adenosine triphosphate
(ATP), nicotinamide adenine dinucleotide (NADH) and other molecules important to cellular
metabolism. Ribose serves as a precursor for the synthesis of purine nucleotides. Cyclic ADP ribose is
also involved as a messenger in insulin secretion.
Parameter Speciﬁcation Method
Microbiological speciﬁcations
Total plate count ≤ 100 CFU/g AOAC 990.12
Yeast ≤ 100 CFU/g AOAC 995.21
Mould ≤ 100 CFU/g AOAC 995.21
Coliforms ≤ 10 CFU/g AOAC 991.14
Salmonella sp. Negative/25 g AOAC 992.11
AOAC: Association of ofﬁcial analytical communities; HPLC/RI: High-performance liquid chromatography coupled with refractive
index detection.
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According to the applicant, at the time of submission of this application to the UK authority (2013),
approximately 1,900 metric tonnes of Bioenergy RiboseTM have been sold in the USA since 2004,
equivalent to approximately 1.3 billion servings. A total of 31 adverse reactions were reported in that
timeframe through the applicant’s post-marketing surveillance programme. All the adverse reactions
reported where in relation with the consumption of food supplements containing D-ribose, while no
adverse reactions were reported for foods fortiﬁed with D-ribose. The adverse reactions reported,
ordered by frequency, were upset stomach (5); transient-elevated blood sugar in diabetic customers
(4); transient racing heart (3); rash (3); itching (3); diarrhoea (3); constipation (2); swollen leg (2);
felt funny (1); weakness/fatigue (1); headache (1); light-headedness (1); excess gas (1); muscle
tightness (1).
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
Upon request of the Panel, the applicant speciﬁed that the target population for the consumption of
D-ribose would be adults and adolescents above 14 years of age.
3.7.2. Proposed uses and use levels
The proposal for intended uses and use levels of D-ribose provided by the applicant is summarised
in Table 3. Proposed uses are based on the food group classiﬁcations detailed within the UK National
Diet and Nutrition Survey (NDNS) report (NatCen Social Research, 2013).
In addition to its proposed uses in fortiﬁed food, the applicant proposes to use D-ribose as a food
supplement at a level of up to 10 g per day.
Table 3: Summary of the individual proposed food uses and use levels for D-ribose
Food category Proposed use
D-ribose per
serving (g)
Serving
size (g)(a)
Use level
(g/100 g)
Biscuits Cereal bars 0.62 31 2.00
Buns, cakes, pastries
and fruit Pies
Mufﬁns 2.20 70 3.14
Chocolate confectionery Chocolate confectionery
(excluding chocolate bars)(b)
0.68 40 1.74
Flavoured Drinks(c) Carbonated soft drinks, not low calorie
(non-cola)
1.00 250 0.40
Milk drinks (excluding malts and shakes) 0.80 200 0.40
Ready-to-drink soft drinks, not low calorie 1.00 250 0.40
Reduced calorie beverages(d) 1.00 250 0.40
Sports, isotonic and energy drinks 3.00 250 1.20
Foods intended for
particular nutritional
uses
Meal replacement beverages 1.00 250 0.40
Meal replacement bars and energy bars 3.00 60 5.00
Fruit and vegetable
juices
Fruit juice 0.50 160 0.31
Vegetable juice 0.50 240 0.21
Sugar confectionery Hard and soft confectionery 0.70 35 2.00
Tea, coffee and water Instant and herbal teas only 1.33 190 0.70
Yogurt, fromage frais
and dairy desserts
Yogurt (including frozen yogurt;
excluding yogurt drinks)
1.50 125 1.20
(a): Serving sizes are based on the UK Food Portion Sizes handbook (FFSA, 2002) and from manufacturers’ websites.
(b): This includes chocolate confectionery, such as chocolate-coated nuts, fruit, caramels, chocolate eggs, bonbons, etc., but
excluding chocolate bars.
(c): Flavoured drinks do not include any sugar-free or low-calorie varieties as these beverages were found to have very low
carbohydrate content, and therefore not a target for D-ribose.
(d): Reduced calorie beverages are only included if they have a carbohydrate content > 0.2 g/100 mL.
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3.7.3. Anticipated intake of the NF
In a tiered approach, the applicant provided estimates of the anticipated intake of the NF based on the
summary statistics from the EFSA Comprehensive European Food Consumption Database, which
generally leads to an overestimation of anticipated daily intakes. For a reﬁned intake estimate of the NF,
the applicant used individual data from the UK NDNS rolling programme covering the period 2008–2012.
In the evaluation of the intake estimates for D-ribose, a new intake assessment was performed by
EFSA based on the individual European Union (EU) data from the EFSA Comprehensive Food
Consumption Database (EFSA, 2011a). The full details of the exposure assessment for the intake of D-
ribose from fortiﬁed foods are provided in Appendix A.
For the estimation of the intake, the Panel considered the uses proposed by the applicant as
reported in Table 3. For the purpose of the exposure assessment, these food categories were
recodiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
The ranges of the estimated daily intake of D-ribose from fortiﬁed foods in the different population
groups considered, based on the EFSA Comprehensive European Food Consumption Database, are
reported in Table 4.
The applicant proposes that D-ribose would be consumed as food supplement at a level up to 10 g
a day. Assuming that food supplements would be consumed only by the target population (i.e. adults
and adolescents above 14 years of age) and considering the default mean body weight values
recommended by the EFSA Scientiﬁc Committee (2012) (i.e. 61.3 kg for adolescents above 14 years of
age male and females and 70 kg for adult males and females) the derived expected daily intakes from
food supplements would be up to 163 mg/kg body weight (bw) per day for adolescents and 143 mg/
kg bw per day for adults.
According to the applicant, D-ribose used as a food supplement would typically be taken as an
alternative to fortiﬁed foods, and therefore, users of D-ribose food supplements would not be expected
to consume the food fortiﬁed with D-ribose that are detailed in Table 3.
3.7.4. Combined intake from the NF and other sources
Intake from the background diet
D-ribose occurs naturally in the human diet as it is present in all living cells as a component of
genetic material and several molecules involved in metabolism. The applicant reported that that low
levels of free ribose are consumed daily through the diet, but concluded that the actual levels are
difﬁcult to quantify due to the impact of processing on the levels within the various foods.
Ribose is reported to be present in meat in varying amounts, e.g. 1–524 mg/100 g beef meat
(Jarboe and Mabrouk, 1974; Gazzani and Cuzzoni, 1985) and 6.4–39.5 mg/100 g chicken meat (Aliani
and Farmer, 2002), with these differences probably attributable not only to the origin of the meat but
also to differences in sampling or analytical methods. Lilyblade and Peterson (1962) reported that the
content of ribose increases post-mortem during storage of chicken meat. The cooking process is
reported to reduce the quantity of free ribose as this is involved in Maillard reactions.
RNA and free nucleotides are reported to be degraded in the intestinal tract and free ribose may
partially be released by the action of nucleosidases (Uauy-Dagach and Quan, 1994; Carver and Walker,
1995).
Due to the lack of data in the literature, the Panel considers that the intake levels of D-ribose from
the background diet are largely unknown.
Table 4: Summary of the ranges of the estimated daily intake of D-ribose from fortiﬁed foods by
population group based on the EFSA Comprehensive European Food Consumption
Database
Estimated
intake
(mg/kg bw
per day)
Infants
(4–11
months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
Estimated D-ribose intake from fortiﬁed foods
Mean 4–222 (6) 44–210 (10) 29–137 (18) 17–71 (17) 7–36 (17) 6–28 (14)
High level (P95) 27–829 (5) 136–553 (7) 102–314 (18) 51–154 (17) 32–106 (17) 26–93 (14)
Between brackets the number of surveys considered per population group.
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Endogenous production
Based on the estimated mean daily intake of carbohydrates in the UK, i.e. 252 and 198 g in men
and women, respectively, (Department of Health, 2011; UKDA, 2012; NatCen Social Research, 2013)
and assuming (i) that 2/3 of these would be composed of glucose, and (ii) that 2–9% of glucose is
utilised via the PPP (Magnusson et al., 1988; Delgado et al., 2004), the applicant estimated that the
daily endogenous production of D-ribose through the PPP ranges from approximately 3–15 g/day.
Additional information on the extent of the daily endogenous production of D-ribose in the literature is
lacking. The Panel concludes that the information is insufﬁcient to draw conclusions on the extent of
the daily endogenous production of D-ribose.
Combined intake from all sources
The Panel notes the limited information available to estimate the intake levels of D-ribose from the
background diet and is therefore not in the position to estimate its contribution to the combined intake
of the NF.
The expected intake of the NF from fortiﬁed foods only, for the different population groups, is
reported in Table 4.
The expected intake of the NF from food supplements in the target population would be up to 163
mg/kg bw per day for adolescents and 143 mg/kg bw per day for adults.
Considering the possible scenario of combined intake of the NF from fortiﬁed foods (derived from
the EFSA Comprehensive European Food Consumption Database) and from food supplements
(estimated using EFSA’s default values for body weight (EFSA Scientiﬁc Committee, 2012)), the
Panel estimated the ranges of intake for the target population groups, i.e. adolescents and adults. The
combined intake estimates are reported in Table 5.
3.8. Absorption, distribution, metabolism and excretion (ADME)
Absorption
In an oral gavage study, rats (body weight: 100–150 g) were administered 2 mL of a 25% sugar
solution containing D-glucose, D-ribose, or D-xylose (corresponding to about 5,000 mg/kg bw) following
a fasting period of 48 h. Compared to glucose (set to 100%), 74% D-ribose was absorbed within the
ﬁrst hour and 67% in the second hour (Naito^, 1944).
In a human study, absorption of orally administered D-ribose at doses up to 200 mg/kg per hour for
5 h was reported to range from 87.8% to 99.8% of the plasma levels obtained after application of the
same intravenous dose/hour (Gross et al., 1989). The same study reported that serum levels of ribose
increased from 1.6 mg/dL (range 0.0–3.5 mg/dL) at baseline to a mean concentration of 4.8 mg/dL at
the oral dose of 83 mg/kg per hour, to 32.6 mg/dL at the oral dose of 167 mg/kg per hour and up to
around 80 mg/dL at the intravenous dose of 222.2 mg/kg per hour. Both after oral and intravenous
administration, a steady state of urinary excretion of ribose occurred after 60–180 min, which was
about at the same time as the steady state of the serum concentration of ribose.
Twelve healthy adults (mean body weight 72.7 kg) were administered orally (i) solutions containing 2.5,
5.0 and 10.0 g D-ribose (corresponding to 34, 69 and 138 mg/D-ribose per kg bw) under fasting conditions
and (ii) 10.0 g D-ribose under fed conditions with either a high fat (N = 6) or high carbohydrate (N = 6)
meal (Thompson et al., 2014). D-ribose was absorbed rapidly (mean Tmax 18–30 min) and Cmax and Area
under the curve (AUC) increased more than proportionally with dose, indicating saturation of metabolism.
Under fed conditions, Tmax was unchanged; however, Cmax and AUC decreased with both kind of meals
(by 42.6% and 40.8%, respectively, with high fat meals and by 69.1% and 64.9%, respectively, with high
carbohydrate meal) indicating that the absorption of ribose decreased during the meals.
Table 5: Summary of the ranges of the estimated combined daily intake of D-ribose from fortiﬁed
foods and from food supplements for the target population groups, based on the EFSA
Comprehensive European Food Consumption Database
Estimated intake
(mg/kg bw per day)
Adolescents
(10–17 years)(a)
Adults
(18–64 years)
The elderly
(≥ 65 years)
Mean 180–234 150–179 149–171
High level (P95) 214–317 175–249 169–236
(a): According to the applicant, only adolescents above 14 years of age would be part of the target population.
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Segal and Foley (1958) administered various quantities of 14C-ribose to healthy subjects by
intravenous infusion for 15 min. The authors reported a linear disappearance of 14C-ribose from blood
when 3 g (43 mg/kg if a body weight of 70 kg is assumed) was injected, but a lag phase prior to the
onset of a linear disappearance when doses greater than 3 g were administered, indicating saturation
of metabolism.
Distribution
Goncalves et al. (1969) used 3H-ribose to investigate the fate of D-ribose within the body via
autoradiography. Rats were injected either intraperitoneally or intravenously 3H-ribose. After 5–60 min,
animals were sacriﬁced and distribution of radioactivity was analysed by light and electron microscopy.
To identify the chemical nature of the label, tissues were treated with RNAse, DNAse and amylase and
disappearance of the label was monitored. Radioactivity was broadly distributed in the body, with
highest amounts in hepatocytes. Radioactivity was associated with RNA, DNA and glycogen. In
addition, amylase resistant radioactivity was detected, especially in cells of secretory glands.
100 mg/kg bw 14C-ribose was injected subcutaneously into rats. 5, 10, 30, 45, 60 and 120 min
later the rats were sacriﬁced and radioactivity was determined in liver, brain and blood. Radioactivity
was taken up in liver and brain with the uptake being several fold greater in liver than in brain. Highest
radioactivity was found in the liver within 5 min after application. Lower amounts (about half of the
values or less per g tissue) were found in the brain and at later time points (Gaitonde and Arnfred,
1971).
Metabolism
Several studies in rats, mice and humans show that D-ribose enters the PPP and is mainly
transformed to glucose (Gaitonde and Arnfred, 1971; Hiatt, 1958; Naito^, 1944; Segal and Foley, 1958),
which is then used for biosynthesis of glycogen (Naito^, 1944; Hiatt, 1958; Goncalves et al., 1969),
converted to sugar phosphates, amino acids and carboxylic acids (Gaitonde and Arnfred, 1971),
glycoproteins (Goncalves et al., 1969) or is degraded to CO2 (Segal and Foley, 1958).
Gaitonde and Arnfred (1971) investigated the time course of appearance of metabolites and
distribution in liver, blood and brain. Within 5 min after subcutaneous injection of 100 mg 14C-ribose/
kg bw to rats, the major metabolite (50%) in blood and liver was glucose, only 1% of the radioactivity
was found in ribose. In the liver and blood, 14C was mostly found in free sugars (mainly glucose)
during the ﬁrst half hour after administration, but later more 14C was found in carboxylic acids,
nucleotides and sugar phosphates. In the brain in contrast, the majority of 14C was found in amino
acids, carboxylic acids, nucleotides and sugar phosphates rather than free sugars.
When ribose was injected subcutaneously to mice, which had been starved for 24 h, the glycogen
content in the liver was increased, but more retarded and to a smaller degree as for the same amount
of glucose (Naito^, 1944).
Only to a limited extent, D-ribose is used directly as a precursor for the synthesis of RNA and DNA
(Goncalves et al., 1969; Gaitonde and Arnfred, 1971).
Excretion
In clinical studies administering D-ribose to patients either orally or intravenously, Gross et al.
(1989), reported that the renal excretion of D-ribose as percentage of intake was on average 5.0%,
15.4% and 16.6% at oral intakes of 83.3, 166.7 and 200 mg/kg per hour, respectively, and 7.9%.
19.3% and 23.1% at intravenous infusion of 83.3, 166.7 and 222.2 mg/kg per hour, respectively.
In the clinical study by Thompson et al. (2014), described above, the amount of D-ribose in urine
increased from 4.15% to 7.20% of the administered dose after oral application of 2.5, 5.0 and 10.0 g
D-ribose.
After 15 min of intravenous infusion of 14C-ribose, 10% of 14C appeared in the urine, when only the
radiolabelled tracer (5 mg) was applied (Segal and Foley, 1958). When 20 g D-ribose (about 285 mg/
kg bw, if body weight of 70 kg is assumed) were infused, excretion in the urine rose to 40% indicating
saturation of uptake into cells. While the substance excreted in the beginning was ribose, at later time
points other (not identiﬁed) substances prevailed. In parallel with increased excretion via urine, the
amount excreted as CO2 within the following 6 h decreased from 48% to 16%.
Overall conclusion on ADME
The Panel notes that the information on absorption and excretion of D-ribose in rats is limited. In a
study performed in humans, D-ribose is rapidly and nearly completely absorbed when administered at
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200 mg/kg bw per hour for 5 h. At dose levels above 3 g (about 40 mg/kg bw) in humans, absorption
was faster than metabolism. Application of D-ribose with meals decreases absorption. In the body,
D-ribose is converted mainly to glucose via the PPP (rather than to nucleic acid precursors), which then
is further used in the metabolism. Part of the ribose and its metabolites is excreted via the urine and
the percentage increases with increasing dose.
3.9. Nutritional information
D-ribose is a ﬁve-carbon sugar that is ingested with foods as an integral part of RNA and free
nucleotides in cells, as well part of riboﬂavin which belongs to the group of B-vitamins. Orally
administered free D-ribose was well absorbed in humans (Gross et al., 1989; see also Section 3.10.4).
D-ribose is not an essential nutrient as it is formed from other monosaccharides via the PPP.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
3.10.1. Genotoxicity
A bacterial reverse mutation test was performed in Salmonella Typhimurium strains TA1535,
TA1538, TA98, and TA100 as well as Escherichia coli strain WP2 uvrA (in compliance with OECD
TG 471; van Ommen, 1999). Five concentrations of D-ribose were used for each bacterial strain: from
62 to 5,000 lg/plate in the ﬁrst assay, and from 313 to 5,000 lg/plate in the second assay, both in
the absence and presence of a metabolic activation system (S9 mix). D-ribose did not cause a
biologically relevant increase in the mean number of revertant colonies compared to the negative
control (solvent) in all strains tested, both in the absence and presence of metabolic activation.
D-ribose was evaluated for its potential to induce structural chromosomal aberrations in Chinese
hamster ovary cells (in compliance with OECD TG 473; de Vogel, 2000a). The cells were incubated
with the test substance at concentrations up to 1,500 lg/mL for 4 h in the absence and presence of
metabolic activation or 18 h in the absence of metabolic activation. No cytotoxicity was observed.
D-ribose did not induce a statistically signiﬁcant increase in the number of cells with structural
chromosomal aberrations at any of the concentrations and time points analysed when compared to
control (solvent) values.
In a mammalian gene mutation assay, D-ribose was tested for its ability to induce gene mutations
at the TK-locus of cultured mouse lymphoma L5178Y cells (in compliance with OECD TG 476;
Steenwinkel, 2000). No cytotoxicity or dose-related increases in mutant frequency were observed
following treatment with D-ribose, either in the absence or presence of a metabolic activation system
(S-9 mix), at concentrations of 0.21–10 mM. Both in the presence and absence of metabolic activation
the mutant frequency was increased not dose dependently at single dose levels in one of two trials.
These ﬁndings were not reproduced in the second trial.
In an in vivo bone marrow micronucleus study, either 2,000 mg D-ribose/kg bw or vehicle control
(maize oil) were administered to 10 male and 10 female mice (in compliance with OECD TG 474; de
Vogel, 2000b). The mice were sacriﬁced either 24 or 48 h after treatment. The number of
polychromatic erythrocytes per 1,000 erythrocytes in D-ribose-treated mice did not differ signiﬁcantly
compared to negative controls; however, exposure to the bone marrow is evident as D-ribose is
absorbed into systemic circulation. The incidence of micronucleated polychromatic erythrocytes per
1,000 polychromatic erythrocytes in mice treated with D-ribose was not signiﬁcantly higher than those
observed in negative controls.
Even though the genotoxicity testing strategy is not fully in line with current EFSA
recommendations (EFSA Scientiﬁc Committee, 2011), as no in vitro mammalian micronucleus test was
provided, the Panel considers that there is no concern with respect to genotoxicity of the NF.
3.10.2. Subchronic toxicity
The applicant provided a subchronic (90-day) toxicity study performed with Bioenergy RiboseTM
(in compliance with OECD TG 408; Grifﬁths et al., 2006; Jonker, 2005). Groups of Wistar rats (20 male
and 20 female per group) were administered diets containing 0, 5, 10, or 20% D-ribose. Control rats
received a basal diet where barley in normal rodent diet was replaced (amounting to 20% of the diet)
by 20% pregelatinised potato starch. D-ribose was added at the expense of potato starch to the diet
(i.e. 5% D-ribose and 15% potato starch, 10% D-ribose and 10% potato starch, 20% D-ribose).
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Based on the food consumption measured during the study, the intake of D-ribose was equivalent to
mean daily intakes of 0.0, 3.6, 7.6 and 15.0 g/kg bw per day in males and 0.0, 4.4, 8.5 and 15.7 g/kg
bw per day in females.
In the last week of the treatment period, urine was collected in 10 rats per sex. The urine was
collected on two subsequent days, the ﬁrst day under non-fasting condition, and the second day under
fasting conditions.
All animals survived to scheduled necropsy apart from one male in the mid-dose group (judged as
incidental).
Terminal body weights were lower in all dose groups than in the control group (statistically
signiﬁcant in mid-dose females and in high-dose animals of both sexes). With the exception of the ﬁrst
weeks of treatment, and some time points later, the mean feed consumption and feed conversion
efﬁciency values were comparable across all study groups.
Ophthalmoscopic examination of the animals during the last week of the study did not reveal
treatment-related abnormalities.
In haematological analysis, neutrophils were signiﬁcantly increased and lymphocytes signiﬁcantly
decreased in the male high-dose group. Signiﬁcantly lower haemoglobin and packed cell volumes in
females (all dose levels) were considered as not treatment related, as there was no relation to dose
and the control value was unusually high, compared to historical control values.
Clinical chemistry indicated some statistically signiﬁcant ﬁndings. The following parameters were
affected: alkaline phosphatase (increased in males in the high-dose group); aspartate amino
transferase (increased in mid and high dose females); total protein (decreased in high-dose males and
females); albumin (decreased in high-dose males); albumin/globulin ratio (increased in high-dose
males and mid- and high-dose females); cholesterol (decreased in high-dose males); triglycerides
(decreased in high-dose males); phospholipids (decreased in high-dose males). No changes in glucose
serum levels in non-fasted and fasted rats were observed.
Higher water intake and urine volume (statistically signiﬁcant for the 20% ribose male and female
animals) were observed. The statistically signiﬁcant decrease observed in all parameters in urinalyses for
animals in the highest dose group (density, glucose, glucose creatinine molar ratio, pH) was therefore
attributed by the authors to the dilution due to the increased urinary volume. In addition, excretion of
glucose per 24 h and per mole of creatinine was signiﬁcantly decreased in mid- and high-dose females.
Low-dose females and mid- and high-dose males showed a similar tendency, but the differences from
controls were not statistically signiﬁcant.
Compared to the control, absolute kidney weights were decreased in both high-dose males and
females. Relative kidney weights were signiﬁcantly increased in all treated males. Absolute liver weights
were decreased in high-dose males and increased in low- and mid-dose females. Relative liver weights
were increased in mid-dose males and all treated females. Both, absolute and relative full caecal
weights were signiﬁcantly higher in both sexes. Absolute empty caecal weights were increased in all
dose levels in male and female rats, relative empty caecal weights in the mid- and high-dose animals.
Absolute brain weights were decreased in high-dose animals, but relative weights were increased in
mid-dose females and high-dose regimens in both sexes. Absolute spleen weight was increased in
mid-dose males. Relative spleen weights were increased in both mid- and high-dose animals. Absolute
lung weights were decreased in high-dose males and females. Absolute thymus weights were
decreased in both sexes in the high-dose group, relative thymus weight in low- and high-dose males.
Relative testes weight was increased in high-dose males, relative seminal vesicle weight was increased
in low-dose males and absolute epididymis weight was decreased in high-dose males.
At necropsy, no consistent macroscopic pathological ﬁndings were noted other than the yellow
discolouration of abdominal fur in all mid- and high-dose animals, which was attributed to excessive
urinary output of these animals. Microscopic evaluation of numerous tissues revealed no changes that
could be attributed to the intake of D-ribose.
The Panel notes the very high-dose levels tested in this study, which makes it difﬁcult to distinguish
between nutritional imbalance effects and toxicological effects. The control animals received 20%
potato starch replacing the barley of the normal rodent diet to adjust for nutritional imbalances. As no
historical control data were provided, it cannot be judged, whether the potato starch in the diet per se
also would cause effects, which would mask effects of D-ribose.
The Panel notes that the most prominent ﬁndings after application of D-ribose to rats for 90 days
are decreased body weight, increases in water intake and urine volume (and dilution of the urine), full
and empty caecum weight, liver and other organ weights.
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In the 5% group in both sexes, reductions in body weight, compared to the control group are
below 5%, in the 10% group in female rats, it is about 7% and statistically signiﬁcant. The Panel has
no information, whether the control diet containing potato starch, compared to the conventional
rodent diet containing barley would itself result in reduced body weight. Therefore, a much higher
effect of ribose on body weight, compared to conventional diet may be possible.
Increased full and empty caecum weight is a common ﬁnding in rats fed high amounts of mono-
and disaccharides as well as polysaccharides, e.g. sorbitol, lactose and some starches. These effects,
which are not associated with histopathological changes in the caecum, are regarded as physiological
adaptation to the presence of incompletely digestible carbohydrates (Leegwater et al., 1974; JECFA,
1978). In the absence of histopathological changes in the microscopic examination of the caecum in
the study with D-ribose, the Panel does not consider the observed changes in caecum weight as
toxicologically relevant.
Increased water intake is considered a result of osmolar imbalance and leads to dilution of urine.
The Panel notes, however, that reductions in the amount of glucose in 24h urine and in relation to
creatinine cannot be explained by dilution of the urine. As D-ribose affects the amount of glucose in
the blood – as known from studies in humans – this ﬁnding may reﬂect some metabolic changes.
Whether these effects are adverse is unknown.
Furthermore, increased absolute and relative liver weights at the low- and mid-dose levels can be
attributed to adaptation to D-ribose metabolism, while the drop in liver weight at the highest dose level
then may reﬂect a toxic effect. Effects on liver weight are accompanied by slight increases in serum
alkaline phosphatase and aspartate aminotransferase and decreases in total protein.
The Panel considers other changes in organ weights rather as secondary to the reduced body
weight.
Based on the reduced body weights in combination with the other ﬁndings outlined above, the
Panel considers that the no observed adverse effect level (NOAEL) for this study in the rats is 5% in
the diet corresponding to 3.6 g/kg bw per day.
3.10.3. Reproductive and developmental toxicity
The applicant provided a developmental toxicity study in which 12-week-old albino Wistar rats were
mated and the females were administered Bioenergy RiboseTM from gestational day 0 to 21 (in
compliance with OECD TG 414; Grifﬁths et al., 2007; Wolterbeek and Waalkens-Beren, 2005). D-ribose
was administered to 28 rats/group at 0, 5, 10 or 20% of the diet. Based on feed consumption this
results in an average dose of 0.0, 4.25, 7.94 and 9.91 g/kg bw per day, respectively. Control rats
received a basal diet where barley was replaced by 20% potato starch. D-ribose was added at the
expense of potato starch to the diet.
All animals survived to the scheduled caesarean section on day 21. Food consumption was
decreased in all treatment groups in the ﬁrst 2 weeks and in the high-dose group in week 3. The
mean body weight gain was signiﬁcantly decreased in the mid- and high-dose groups over each of the
ﬁrst 2 weeks of the study, but then recovered during the third week such that the mean terminal body
weights were not statistically signiﬁcantly different.
The authors reported that gross observations at scheduled necropsy and caesarean section on day
21 were unremarkable. Neither absolute nor relative weight of the liver was affected by treatment at
any dose, but caecal weights, both absolute and relative, were signiﬁcantly increased relative to
controls at all three-dose levels.
With regard to reproduction data, the treatment with D-ribose did not affect fecundity index,
gestation index, preimplantation loss, post-implantation loss and sex ratio. External observations of
foetuses and placentas were also unremarkable in all the study groups. No signiﬁcant differences were
observed, across all viable foetuses between treated and control groups for mean foetal and placental
weights. Similarly, observations of visceral malformations, anomalies and variations were unremarkable
and did not differ between treated and control groups. Signiﬁcant skeletal malformations and
variations were also not observed between groups.
The incidences for one wavy rib and for two or more wavy ribs did not reach statistical signiﬁcance
when analysing foetuses and litters separately. However, when the incidences of foetuses showing one
wavy rib or two or more wavy ribs are grouped together, the incidence of foetuses and the incidence
of litters showing one or more wavy ribs was statistically signiﬁcantly increased in the mid- and
high-dose groups (p < 0.05). Furthermore, dose dependent and statistically signiﬁcant differences
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between control and treated groups in the incidences of incomplete ossiﬁcation of the frontal, parietal
and interparietal bones were reported.
The Panel notes that besides maternal toxicity (reduced body weight gain), wavy ribs and delayed
ossiﬁcation were detected in the foetuses primarily in the mid- and high-dose groups. Both these
foetal effects are observed frequently in developmental toxicity studies and are often secondary to
maternal toxicity (Carney and Kimmel, 2007). The NOAEL for maternal toxicity/foetotoxicity is
consequently 5% D-ribose in the diet, corresponding to an average intake of 4.25 g/kg bw per day,
while the NOAEL for teratogenicity is 20%, the highest level of D-ribose tested.
3.10.4. Human data
The applicant provided human studies on the oral consumption of D-ribose performed with
Bioenergy RiboseTM and with D-ribose from other sources.
Studies on oral consumption of D-ribose for several days or weeks
Only one study (Seifert et al., 2008) aimed to assess the safety of D-ribose whereas the others
were efﬁcacy studies with the recording of side effects.
In the uncontrolled study by Seifert et al. (2008), 19 healthy adults, 19–25 years, were
administered 10 g of Bioenergy Ribose twice daily for 14 days. Haematological and biochemical
parameters were analysed at baseline and on days 7 and 14 in fasted states. There were no
statistically signiﬁcant differences from baseline to day 7 and day 14 in all subjects for haemoglobin,
haematocrit, white blood cells, platelets, alkaline phosphatase, aspartate aminotransferase and alanine
aminotransferase. Minor changes were reported at day 7 (but not at day 14) when compared to
baseline for gamma glutamyltransferase (18.3  8.62 vs 21.2  13.57 U/L, p < 0.03) and for albumin
(5.082  0.003 vs. 5.073  0.002 g/dL, p < 0.01). Plasma glucose levels slightly declined, though not
statistically signiﬁcantly, throughout the study period (day 0: 3.64  0.80, day 7: 3.55  0.85, day 14:
3.23  1.03 mmol/L). Uric acid levels were non-signiﬁcantly elevated (within the normal range) in all
subjects at day 7 (on average from about 315 lmol/L to 345 lmol/L, read from ﬁgure). No adverse
physical symptoms, including gastrointestinal problems, occurred in any subject during the study.
In a randomised, double-blind crossover study (Hellsten et al., 2004), eight healthy subjects (25 
1.8 years) underwent exercise training for 7 days followed by Bioenergy RiboseTM administration of a
total of nine oral doses, each of 200 mg/kg bw over a period of three days (corresponding to 52 g/day
for a mean body mass of 86.2 kg) and a subsequent training session 72 h after the last training
session (‘72-h test’). After the last training session, plasma glucose levels were signiﬁcantly lower (p <
0.05) in the D-ribose group compared to placebo at 30, 60 and 90 min (with lowest values of 3 mmol/
L at 60 min) and compared to resting levels at 60 and 90 min but returned to baseline within 2 h. In
the D-ribose group, an increase in plasma urate levels (up to 475 lmol/L, read from ﬁgure) was also
observed compared to levels immediately after training, and to placebo from 10 min after exercise in
the 72-h test.
Van Gammeren et al. (2002) reports on a double-blind, placebo-controlled trial in 12 bodybuilders
aged 18–35 years in which 5 g Bioenergy D-ribose was consumed 30–60 min before and after training
for 4 weeks. No adverse events (i.e. diarrhoea, gastrointestinal distress or muscle cramping) were
reported.
In a randomised, double-blind, crossover study, Omran et al. (2003) investigated the effect of
consuming 15 g/day of Bioenergy’s D-ribose, given in three portions of 5 g with meals for 3 weeks in
15 coronary artery disease (CAD) patients, mean age 61  6 years. No adverse effects were reported.
In a double-blind, placebo-controlled, crossover study, Steele et al. (1966) investigated the effects
of 15 g D-ribose, given four times daily after meals for 7 days in ﬁve patients with McArdle’s disease,
age 20–60 years. The symptoms observed were diarrhoea (1), occasional symptoms of hypoglycaemia
(1), light-headedness (1) and hunger (1).
Teitelbaum et al. (2006) investigated the effects of CORvalenTM (a ribose-based product produced
by Bioenergy) therapy in 41 chronic fatigue syndrome and/or ﬁbromyalgia patients, average age 48
years, in an open-label uncontrolled pilot study. Patients ingested 5 g D-ribose three times daily with
food for an average duration of 28 days. Of the ﬁve subjects considered non-compliant, three patients
withdrew from D-ribose treatment because of a hyperanxious feeling, light-headedness and increased
appetite. Among the study completers, one reported transient nausea and 1 reported mild anxiety, but
both reactions were reversed by dose reduction.
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Gebhart and Jorgenson (2004) reported on a 37-year-old woman diagnosed with ﬁbromyalgia who
received 5 g CORvalenTM, twice a day for over 2 months with no adverse effects reported during the
treatment period.
Pliml et al. (1992) studied the effects of four doses of 15 g D-ribose per day for 3 days in 20 CAD
patients, aged 45–69 years. Ribose was generally well tolerated, with episodes of slight discomfort (in
two patients at 30 min and 2 h, respectively, after the ﬁrst dose of ribose; the symptoms were not
typical of hypoglycaemia) and mild gastrointestinal discomfort (1 on day 3). Three patients had an
increase in serum uric acid levels to 410–500 lmol/L (7.4–8.4 mg/dL).
A myoadenylate deaminase deﬁcient patient ingested D-ribose up to 50–60 g D-ribose per day
(Z€ollner et al., 1986) for an unspeciﬁed period. Daily amounts subdivided into 4 g doses were tolerated
without side effects, whereas single doses of more than 20 g resulted in diarrhoea.
Salerno et al. (1998) investigated the effects of D-ribose administration in a 13-year-old female
patient with adenylosuccinase deﬁciency. The patient consumed 40 g D-ribose/day in four 10 g doses
for 3 months without adverse effects, while higher doses of up to 100 g/day resulted in mild
diarrhoea. Uric acid excretion markedly increased. Serum urate levels increased from 0.12 to 0.29
mmol/L and glucose levels decreased from 5.4 to 4.8 mmol/L. In healthy subjects, oral administration
of 13 mmol (approx. 1.95 g)/kg bw per day of D-ribose resulted in a 10–20% decrease in serum
glucose levels, and a two- to threefold increase in urate and urinary urate-to-creatinine ratio. D-ribose
was well tolerated, with the exception of occasional diarrhoea at higher doses, up to about 30 mmol
(approx. 4.5 g)/kg bw per day (Salerno et al., 1999).
Studies on the effects of oral single administration of D-ribose
In the double-blind, randomised cross-over study of Thompson et al. (2014) (see Section 3.8), 12
healthy, adult subjects were given oral doses of 2.5, 5.0 and 10.0 g D-ribose under fasting and fed
conditions. Serum glucose decreased at fasting in a dose-related manner with respective baseline/post
dose values of 86.5/83.1, 85.8/72.6 and 86.8/60.5 mg/dL. Dose-related decreases in serum glucose up
to 26.3 mg/dL (30.3% of baseline at the 10 g dose) occurred in the ﬁrst 60 min post dose and
returned to near-normal at 2 h, but remained slightly below predose levels up to the last time point (5
h). Insulin response peaked 15 min post dose. The presence of food did not appreciably affect the
lowering of glucose levels compared with the comparable fasting dose. The uric acid levels were
virtually unchanged for all fasting doses of D-ribose. The increases in uric acid in the fed state were
attributed to the food consumed. D-ribose was generally well tolerated in the dose range studied,
though one of the subjects, a 53 kg female for a few minutes experienced mild symptoms of
hypoglycaemia 70 min post dose of 10 g ribose in the fasted state.
Fenstad et al. (2000) investigated the effects of D-ribose on resting carbohydrate and purine
metabolism in 10 healthy subjects, aged 18–50 years, who were given oral doses of 0, 2, 5 and 10 g
of Bioenergy RiboseTM on different days. Blood samples were obtained at 0, 15, 30, 45, 60 and 120
min after the consumption of each dose. A dose-dependent decrease in blood glucose was observed
for all D-ribose dosages. Both the 5 and 10 g doses resulted in an acute, temporary state of
hypoglycaemia (3 mmol/L and 2.6 mmol/L, respectively), but only with the 10 g dose, the decline
reached signiﬁcance (p < 0.05) at 45 and 60 min after ingestion. At any dose of D-ribose, no adverse
subjective effects were noted and at 120 min post-consumption, blood glucose had returned to
baseline values. A non-signiﬁcant increase in insulin values was observed for all doses which peaked at
15 min and then declined to or below baseline. Levels of uric acid differed with differing doses of
D-ribose (2 g: 297  10 lmol/L; 5 g: 328  0.9 lmol/L; 10 g: 318  0.9 lmol) and paired comparison
from 2 g and 5 and 10 g was statistically signiﬁcant at 30 and 60 min after ingestion (p < 0.05).
Gross and Z€ollner (1991) administered D-ribose orally after an overnight fast to nine healthy
subjects, aged 23–37 years at doses ranging from 83.3 to 166.7 mg/kg bw per hour over at least 4 h,
to evaluate the effect on serum levels of glucose, insulin and C-peptide. At 166.7 mg/kg bw per hour,
equivalent up to a total amount of 87 g D-ribose, a 25% decline in serum glucose levels was observed
and a signiﬁcant increase in serum insulin concentrations compared to initial levels; however, levels
remained within normal ranges for the duration of the study.
In another study by Gross et al. (1989), healthy (n = 8, age 23–37 years) and myoadenylate
deaminase deﬁcient (n = 5, age 31–58 years) subjects were administered orally D-ribose at doses up to
200 mg/kg bw per hour for 5 h (corresponding to a total amount of 33–78.5 g for healthy subjects
and to 27–74 g for patients). In healthy subjects, the decrease in serum glucose concentrations
ranged from 8.9% to 29.5%. All doses were well tolerated, except for 200 mg/kg bw per hour, which
resulted in diarrhoea, present in one case also at 166.7 mg/kg bw per hour. No changes in heart rate,
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blood pressure, serum uric acid concentrations, uric acid clearance and creatinine clearance were
reported before, during or after D-ribose treatment.
Ten healthy subjects, aged 20–30 years, were given orally 1 g/kg bw D-ribose (Ginsburg et al.,
1970). Blood samples were taken for 3 h. Following administration, the blood glucose level fell on
average 14 mg/dL over the ﬁrst hour from a fasting mean value of 80 mg/dL, then rose slightly during
the second hour and fell again to a mean of 50 mg/dL at 3 h. Plasma insulin levels signiﬁcantly
increased within half an hour of ribose administration, followed by a slight fall and a second increase
occurring between 2 and 3 h post-ribose administration. This increase accompanied the secondary
decrease in glucose levels. Serum-free fatty acid levels fell by nearly 50% within half an hour of giving
ribose (from a fasting mean of 432 meq/L to 250 meq/L at half an hour and fasting levels were
regained after a further 2 h. Symptoms reported by subjects included headache (1), marked peristalsis
and borborygmi (1) and diarrhoea 3–4 h after ribose ingestion (2).
In ten healthy subjects, aged 21–33 years, who ingested 35 g D-ribose, insulin levels had increased
slightly after 15 min, peaked at 20 min to twice the baseline levels and then rapidly declined
(Goodman and Goetz, 1970). Blood glucose levels were also decreased with lowest levels not below
75% of baseline values within the follow-up period of 90 min.
Steinberg et al. (1970) administered a single oral dose of D-ribose (15 g to 13 healthy subjects, six
probable diabetics, and 15 diabetics), all in the post-absorptive state. Blood samples were collected at
30, 60, 90 and 120 min post-administration. Serum glucose levels decreased in all subjects except for
insulin-dependent diabetics. With increasing glucose intolerance, subjects were signiﬁcantly less
responsive to the blood glucose-lowering effect of D-ribose. The mean maximal decrease of 47%
(27 mg/dL) was observed in healthy subjects after 60 min. Levels returned towards baseline values at
120 min. No signiﬁcant changes in insulin levels were observed.
The Panel notes that in studies lasting several days or weeks, except for one study (Steele et al.,
1966), which reported symptoms of hypoglycaemia in one patient with McArdle disease at intakes of
60 g/day, no symptoms of hypoglycaemia were observed after oral administration of D-ribose at
dosages of 10 g/day up to 1.95 g/kg bw per day in healthy subjects and patients. A non-signiﬁcant
decrease in glucose and increase in uric acid concentration were seen in healthy subjects consuming
20 g/day of D-ribose for 14 days (Seifert et al., 2008). In healthy subjects ingesting 52 g of D-ribose
for 3 days, a signiﬁcant short-term decrease in glucose and increase in uric acid levels was found in
relation to a training session (Hellsten et al., 2004). Gastrointestinal symptoms such as discomfort or
diarrhoea were reported to occur occasionally at intakes of single doses > 20 g (Steele et al., 1966;
Z€ollner et al., 1986; Pliml et al., 1992; Salerno et al., 1998, 1999; Teitelbaum et al., 2006).
The Panel notes that single oral administration of D-ribose in amounts of 5–87 g consistently
resulted in a decrease in plasma glucose levels in healthy subjects or patients with lowest values
observed at 45–180 min after D-ribose administration before returning to normal values. The extent of
the decline in glucose concentrations reported in the various studies is mixed and ranged between 9%
and 47%. As far as reported, insulin levels either non-signiﬁcantly or signiﬁcantly increased following
D-ribose administration. In these studies, the decrease in glucose levels was not associated with
symptoms of hypoglycaemia, except for one study (Thompson et al., 2014) in which short-term
symptoms of hypoglycaemia were noted in a low-weight female subject after ingesting 10 g of ribose
in the fasted state. Three of these studies reported also on uric acid concentrations with conﬂicting
results. While Fenstad et al. (2000) found signiﬁcantly higher levels of uric acid (which were, however,
still in the normal range) following oral administration of 10 g D-ribose when compared to the dose of
2 g at 30 and 60 min, no changes in serum uric acid concentrations were reported by Thompson et al.
(2014) following ingestion of 10 g D-ribose and in the study of Gross et al. (1989), during or after
treatment with 27–89 g D-ribose. Gastrointestinal symptoms were noted at single intakes of around
70 g (Gross et al., 1989; Ginsburg et al., 1970).
The studies available on the effects of single administration of D-ribose consistently show a decline
in glucose concentrations at doses of 5 g and above in a dose–response manner. This glucose-lowering
effect has been observed also in the fed state. In one case, the intake of a single dose of 10 g in a
fasted state led to a symptomatic hypoglycaemia. The Panel considers that this blood glucose-lowering
effect of D-ribose is adverse, in that it increases the risk of hypoglycaemia.
3.11. Allergenicity
The applicant has provided evidence that the production process results in the absence of microbial
proteins in the NF by means of a Bradford assay and Kjeldahl analysis.
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In a literature review performed by the applicant, no reports of food allergy resulting from
consumption of B. subtilis-derived food products were identiﬁed. Furthermore, proprietary post-market
surveillance data have indicated no allergic reactions to Bioenergy RiboseTM in the USA, where the NF is
being marketed since 2004.
The Panel considers that the risk of allergic reactions to the NF is low.
4. Discussion
The Panel considers that the observed effects in the subchronic toxicity study in Wistar rats could
be the consequence of nutritional imbalances, but toxicological effects could not be ruled out.
Therefore, the Panel derived a NOAEL of 3.6 g/kg bw per day based on this study.
The developmental toxicity study in Wistar rats provided further information on maternal toxicity
and embryo/foetotoxicity that support the NOAEL deﬁned in the subchronic study.
Concern has been raised by national competent authorities with regard to the potential of D-ribose
intake to cause hypoglycaemia and hyperuricaemia or gastrointestinal symptoms.
In literature, variable glucose levels deﬁne hypoglycaemia (3.3, 3.0, 2.8, 2.7, 2.5 and 2.2 mmol/L,
where the latter is being used to deﬁne severe hypoglycaemia) (Nirantharakumar et al., 2012). In
adults without diabetes, a cut-off of 2.8 mmol/L is often used and symptoms related to low blood
sugar should conﬁrm the diagnosis (Cryer et al., 2009).
Several studies were provided in the dossier with single oral doses of 2–87 g D-ribose consistently
report transient decreases of glucose concentrations within 1–3 h. The transient decrease of glucose
concentration was not associated with clinical symptoms of hypoglycaemia, except for one case, where
a low-weight female experienced short-term symptoms of hypoglycaemia after ingesting 10 g of ribose
in the fasted state. While in this and in most of the other studies, blood glucose levels did not fall
below 2.8 mmol/L, a temporary signiﬁcant decline of blood glucose to 2.6 mmol/L was observed in
one study following a single oral dose of 10 g D-ribose. The decrease in blood glucose comes along
with increases in insulin levels. The glucose-lowering effect also occurs if meals rich in carbohydrate or
fat are ingested before intake of D-ribose.
With regard to a potential impact of D-ribose on increasing serum uric acid, the Panel considers that
the available evidence from human studies does not raise safety concern.
With regard to gastrointestinal symptoms, the Panel considers that available studies indicate that
these may occur with single intakes exceeding 20 g.
No studies have been provided that investigated intake of D-ribose in infants, young children and
adolescents. Whether young age may be of special concern with regard the glucose-lowering effects of
D-ribose is not known. However, the Panel considers that children could be particularly vulnerable to
glucose-lowering effects of D-ribose (Lang, 2011; van Veen et al., 2011; Ramsden et al., 2017).
The Panel notes that there is a lack of understanding of the mechanisms responsible for the short-
term decrease in blood glucose reported in the human studies, only limited data on the dose–response
relationship between D-ribose and blood glucose levels, and uncertainty about the risk of symptomatic
hypoglycaemia, especially in susceptible persons.
Because the decrease in glucose levels and/or the occurrence of transient symptomatic
hypoglycaemia (as reported in one case) is considered adverse, based on the human studies, the
LOAEL would be at intakes of 10 g of D-ribose. Concerning the human data, taking the above issues
into account, the Panel concludes that 5 g per day, equivalent to 70 mg/kg bw per day, would be the
NOAEL with respect to hypoglycaemia that can be considered applicable for adults. For children, the
Panel acknowledges the lack of human data directly relevant for this population group.
For the animal study, the Panel considered an uncertainty factor of 100 as sufﬁcient given the
nature of the NF and the magnitude of the effects observed. Based on the NOAEL of 3,600 mg/kg bw
per day derived from the subchronic toxicity study in rats, an acceptable level of intake would be up to
36 mg/kg bw per day. This is half the NOAEL value identiﬁed in the human studies for adults with
respect to hypoglycaemia. The Panel concludes that 36 mg/kg bw per day would also take into
account the potentially increased sensitivity of certain population groups to hypoglycaemia, including
children.
5. Conclusions
The Panel concludes that the NF, D-ribose, is safe for the general population at intake levels up to
36 mg/kg bw per day.
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The Panel considers that the safety of the NF at the intended uses and use levels as proposed by
the applicant has not been established. Therefore, in line with article 7 of the Commission
Implementing Regulation (EU) 2017/2469, the Panel has provided in Appendix A the detailed dietary
exposure assessment of the NF.
The Panel reached the conclusion on the safety of the NF under the proposed conditions of use
with the data claimed as proprietary by the applicant (oral embryotoxicity/teratogenicity study with
D-ribose in rats [TNO report V2657] and subchronic (13-week) oral toxicity study with D-ribose in rats
[TNO report V99.1155]).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of D-ribose. Ref. Ares(2017)2556092-19/05/
2017.
2) On 1 June 2017, EFSA received a valid application from the European Commission on D-
ribose as NF, which was submitted by Bioenergy Lire Science, Inc., and the scientiﬁc
evaluation procedure started.
3) On 11 September 2017 and 15 January 2018, EFSA requested the applicant to provide
additional information to accompany the application and the scientiﬁc evaluation was
suspended.
4) On 22 November 2017 and 6 February 2018, additional information was provided by the
applicant and the scientiﬁc evaluation was restarted.
5) During its meeting on 17 April 2018, the NDA Panel, having evaluated the data, adopted a
scientiﬁc opinion on the safety of D-ribose as a NF pursuant to Regulation (EU) 2015/2283.
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ACNFP Advisory Committee on Novel Foods and Processes
AOAC Association of ofﬁcial analytical communities
ATCC American type culture collection
ATP adenosine triphosphate
AUC Area under the curve
bw body weight
CFU colony-forming unit
DNA Deoxyribonucleic acid
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GMP Good manufacturing practice
HACCP Hazard analysis and critical control points
HPLC/RI High performance liquid chromatography coupled with refractive index detection
ISO International Organization for Standardization
LOAEL lowest observed adverse effect level
LPS lipopolysaccharide
NADH nicotinamide adenine dinucleotide
NF Novel food
NDNS National Diet and Nutrition Survey
NOAEL No observed adverse effect level
OECD TG Organisation for Economic Co-operation and Development – Test Guideline
QPS Qualiﬁed presumption of safety
RNA Ribonucleic acid
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Appendix A – Intake assessment
The intake assessment of D-ribose was performed with the data available in the EFSA
Comprehensive European Food Consumption Database (Comprehensive database).
Since 2010, the Comprehensive database has been populated with national data on food
consumption at a detailed level. Competent authorities in the European countries provide EFSA with
data on the level of food consumption by the individual consumer from the most recent national
dietary survey in their country (EFSA, 2011a). New consumption surveys added in the Comprehensive
database were also taken into account in this assessment.
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used for exposure calculations, uncertainties could be introduced owing
to possible subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless,
the EFSA Comprehensive database represents the best available source of food consumption data
across Europe at present.
Food consumption data from the following population groups: infants, toddlers, children, adolescents,
adults and the elderly were used for the exposure assessment. For the present assessment, food
consumption data were available from 33 different dietary surveys carried out in 19 European countries
(Table A.1). Consumption records were codiﬁed according to the FoodEx classiﬁcation system
(EFSA, 2011b).
For the estimation of the intake, the Panel considered the uses proposed by the applicant as
reported in Table 3. For the purpose of the intake assessment, these food categories were recodiﬁed
according to the FoodEx classiﬁcation system. Table A.2 provides the list of the food categories used
for the exposure assessment of D-ribose.
Table A.1: Population groups considered for the exposure estimates of D-ribose
Population Age range
Countries with food consumption surveys covering more than
1 day
Infants 4–11 months of age Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers 12–35 months of age Belgium, Bulgaria, Denmark, Finland, Germany, Italy, Netherlands,
Spain, UK
Children(a) 3–9 years of age Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France,
Germany, Greece, Italy, Latvia, Netherlands, Spain, Sweden, UK
Adolescents 10–17 years of age Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France,
Germany, Italy, Latvia, Netherlands, Spain, Sweden, UK
Adults 18–64 years of age Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany,
Hungary, Ireland, Italy, Latvia, Netherlands, Romania, Spain, Sweden,
UK
The elderly(a) From 65 years of
age and older
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Netherlands, Romania, Sweden, UK
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
Table A.2: Food categories used for the exposure assessment of D-ribose based on the FoodEx
classiﬁcation system
Food category FoodEx name FoodEx code
FoodEx
level
D-ribose
use level
(g/100 g)
Biscuits Cereal bars A.01.06.003 L3 2
Buns, cakes, pastries and fruit
pies
Mufﬁns A.01.07.001.036 L4 3.14
Chocolate confectionary Chocolate (Cocoa) products A.10.03 L3 1.7
Chocolate confectionary Bitter chocolate A.10.03.001 L3 1.7
Chocolate confectionary Bitter–sweet chocolate A.10.03.002 L3 1.7
Safety of D-ribose
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2018;16(5):5265
The contribution of each survey to the estimated intake for each population group is provided as
supporting information to this opinion https://doi.org/10.2903/j.efsa.2018.5265.
Food category FoodEx name FoodEx code
FoodEx
level
D-ribose
use level
(g/100 g)
Chocolate confectionary Chocolate, cream A.10.03.004 L3 1.7
Chocolate confectionary Chocolate with nuts or fruits A.10.03.005 L3 1.7
Chocolate confectionary Chocolate-coated confectionery A.10.03.006 L3 1.7
Chocolate confectionary Filled chocolate A.10.03.007 L3 1.7
Chocolate confectionary Milk chocolate A.10.03.008 L3 1.7
Chocolate confectionary White chocolate A.10.03.009 L3 1.7
Chocolate confectionary Pralines A.10.03.010 L3 1.7
Chocolate confectionary Cooking chocolate A.10.03.011 L3 1.7
Chocolate confectionary Cooking chocolate, white A.10.03.012 L3 1.7
Chocolate confectionary Dietetic chocolate A.10.03.013 L3 1.7
Chocolate confectionary Chocolate substitutes A.10.03.014 L3 1.7
Food for particular nutritional
uses
Carbohydrate-rich energy
food products for sports people
A.18.03.001 L3 5
Fruit and vegetable juices Fruit juice A.12.01 L2 0.31
Fruit and vegetable juices Concentrated fruit juice A.12.02 L2 0.31
Fruit and vegetable juices Fruit nectar A.12.03 L2 0.31
Fruit and vegetable juices Mixed fruit juice A.12.04 L2 0.31
Fruit and vegetable juices Vegetable juice A.12.06 L2 0.21
Fruit and vegetable juices Mixed vegetable juice A.12.07 L2 0.21
Sugar confectionary Candies, with sugar A.10.04.001 L3 2
Sugar confectionary Marzipan A.10.04.003 L3 2
Sugar confectionary Caramel, hard A.10.04.004 L3 2
Sugar confectionary Caramel, soft A.10.04.005 L3 2
Sugar confectionary Toffee A.10.04.006 L3 2
Sugar confectionary Fudge A.10.04.007 L3 2
Sugar confectionary Dragee, sugar coated A.10.04.008 L3 2
Sugar confectionary Sugar cotton A.10.04.009 L3 2
Sugar confectionary Foamed sugar products
(marshmallows)
A.10.04.010 L3 2
Sugar confectionary Liquorice candies A.10.04.011 L3 2
Sugar confectionary Gum drops A.10.04.012 L3 2
Sugar confectionary Jelly candies A.10.04.013 L3 2
Sugar confectionary Nougat A.10.04.014 L3 2
Sugar confectionary Halva A.10.04.015 L3 2
Sugar confectionary Chewing gum with added sugar A.10.04.016 L3 2
Tea, coffee, water Herbal tea, infusion A.13.02.004 L3 0.7
Tea, coffee, water Instant tee powder, infusion A.13.02.005 L3 0.7
Tea, coffee, water Instant tea, liquid A.13.02.006 L3 0.7
Yoghurt Yoghurt, cow milk, plain A.08.06.001 L3 1.2
Yoghurt Yoghurt, cow milk, with fruit A.08.06.002 L3 1.2
Yoghurt Yoghurt, sheep milk A.08.06.003 L3 1.2
Yoghurt Yoghurt, goat milk A.08.06.004 L3 1.2
Flavoured drinks Soft drinks(a) A.13.01 L2 0.4
Flavoured drinks Flavoured milk A.08.02.001 L3 0.4
Flavoured drinks Carbohydrate-electrolyte
solutions for sports people
A.18.03.002 L3 1.2
(a): Excluding cola drinks.
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Table A.3 reports the main food categories contributing to the total intake of D-ribose in the
different population groups, estimated from the proposed use levels of D-ribose in fortiﬁed foods using
the EFSA Comprehensive database.
Table A.3: Range of contribution (%) of D-ribose intake from the different food categories used in
the exposure assessment in the EU
Food
category
Infants
(4–11
months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
Biscuits – – – – – –
Buns, cakes,
pastries and
fruit pies
– 6.6 (1) 6.1–7.8 (2) 9.0–21.4 (2) 10.7–20.3 (2) 5.6–5.7 (2)
Chocolate
confectionery
5.5–7.2 (2) 5.2–18.9 (7) 5.0–17.4 (16) 5.6–18.2 (17) 5.7–16.6 (16) 5.4–10.5 (8)
Flavoured
drinks
7.4–14.8 (2) 12.1–30.3 (6) 5.2–68.4 (16) 7.8–79.1 (16) 7.2–86.1 (17) 5.5–33.0 (11)
Foods
intended
for particular
nutritional
uses
– – – – – –
Fruit and
vegetable
juices
5.3–29.6 (5) 10.0–44.2 (10) 7.6–39.5 (17) 8.3–39.3 (16) 10.8–27.5 (15) 6.1–22.1 (13)
Sugar
confectionery
– 6.1 (1) 5.1–14.6 (6) 5.2–16.2 (6) 9.7 (1) 5.9 (1)
Tea,
coffee and
water
7.3–60.6 (3) 5.0–26.3 (4) 6.7–21.7 (7) 6.5–26.3 (8) 10.1–62.4 (11) 5.7–89.4 (12)
Yogurt 14.6–92.8 (6) 5.6–86.0 (9) 6.1–61.5 (17) 10.1–54.5 (15) 10.1–65.4 (15) 9.0–78.9 (13)
Between brackets the number of surveys where the food category contributes to > 5% to the total mean exposure.
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